The prognostic value of osteopontin expression in patients with liver cancer: a meta-analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Xin ,  YUAN Qi , GAO Pengcheng

Department of General Surgery, Zhangye People’s Hospital of Hexi College, Zhangye, Gansu 734000, P. R. Gansu;

Corresponding?author：

YUAN Qi, Email: a13689363739@163.com

Keywords：

liver cancer; osteopontin; prognosis; meta-analysis

DOI：

10.7507/1007-9424.201901001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the prognostic value of osteopontin (OPN) in patients with liver cancer by using meta-analysis.Methods We searched PubMed, Embase, Web of science, Wanfang database, Chinese Science and Technology Academic Journal, Chinese Journal Full-text Database, and Chinese Biomedical Literature Database to identify relevant articles from their inception to October 31, 2018. A meta-analysis was carried out by using the STATA 12.0 software.Results A total of 13 studies were included in this meta-analysis, including 2 171 liver cancer cases. The pooled data of studies showed that OPN expression level was negatively associated with overall survival time (HR=1.58, 95% CI was (1.37, 1.79), P<0.001) and disease free survival time (HR=1.67, 95% CI was (1.39, 1.96), P<0.001). High expression of OPN for patients with liver cancer had shorter overall survival time and disease-free survival time compared with those of low expression of OPN.Conclusion Current evidence shows that high expression of OPN is closely related to poor prognosis of patients with liver cancer.

Citation： ZHANG Xin, YUAN Qi, GAO Pengcheng. The prognostic value of osteopontin expression in patients with liver cancer: a meta-analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(6): 711-718. doi: 10.7507/1007-9424.201901001 Copy

1.	陳萬青, 孫可欣, 鄭榮壽, 等. 2014 年中國分地區惡性腫瘤發病和死亡分析. 中國腫瘤, 2018, 27(1): 1-14.
2.	Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol, 2015, 44(6): 479-486.
3.	Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis, 2018, 9(3): 356.
4.	Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol, 2006, 132(11): 709-717.
5.	Xie H, Song J, Du R, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis, 2007, 39(2): 167-172.
6.	Korita PV, Wakai T, Shirai Y, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol, 2008, 39(12): 1777-1783.
7.	Yang GH, Fan J, Xu Y, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist, 2008, 13(11): 1155-1165.
8.	Kim JY, Bae BN, Kim KS, et al. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat, 2009, 41(1): 29-35.
9.	Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 2003, 98(1): 119-127.
10.	Sieghart W, Wang X, Schmid K, et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol, 2011, 54(1): 89-97.
11.	Tsai WC, Tsai WC, Lee HS, et al. Association between osteopontin and EGFR expression with clinicopathological parameters in hepatocellular carcinoma. Chin J Physiol, 2012, 55(6): 412-420.
12.	Deng B, Zhang XF, Zhu XC, et al. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection. Oncol Rep, 2013, 30(6): 2795-2803.
13.	Jin Y, Chen JN, Feng ZY, et al. OPN and αvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma. PLoS One, 2014, 9(2): e87930.
14.	Ying X, Zhao Y, Wang JL, et al. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. Oncol Rep, 2014, 32(4): 1550-1556.
15.	Chimparlee N, Chuaypen N, Khlaiphuengsin A, et al. Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis B-related hepatocellular carcinoma. Asian Pac J Cancer Prev, 2015, 16(16): 7211-7217.
16.	王代宏, 王偉, 王芳元. 聯合檢測 VEGF、OPN 對原發性肝癌術后復發轉移及預后的意義. 湖北科技學院學報: 醫學版, 2015, 29(4): 280-283.
17.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
18.	Oldberg A, Franzén A, Heineg?rd D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A, 1986, 83(23): 8819-8823.
19.	Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 2007, 56(6): 782-789.
20.	Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 2003, 9(4): 416-423.
21.	許英藝, 張雅雅, 盧偉鋒, 等. 骨橋蛋白表達與中國人肝癌及其臨床病理特征關系的 Meta 分析. 中國循證醫學雜志, 2014, 14(12): 1418-1423.
22.	Zhang CH, Xu GL, Jia WD, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer, 2012, 130(11): 2685-2692.
23.	Cheng J, Wang W, Sun C, et al. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol, 2014, 48(9): 806-814.
24.	Caruso DJ, Carmack AJ, Lokeshwar VB, et al. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res, 2008, 14(13): 4111-4118.
25.	Park MG, Oh MM, Yoon JH, et al. The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: a prospective study. Kaohsiung J Med Sci, 2012, 28(10): 526-530.
26.	Briese J, Cheng S, Ezzat S, et al. Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res, 2010, 30(5): 1681-1688.
27.	Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004, 10(1 Pt 1): 184-190.
28.	Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012, 55(2): 483-490.

1. 陳萬青, 孫可欣, 鄭榮壽, 等. 2014 年中國分地區惡性腫瘤發病和死亡分析. 中國腫瘤, 2018, 27(1): 1-14.
2. Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol, 2015, 44(6): 479-486.
3. Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis, 2018, 9(3): 356.
4. Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol, 2006, 132(11): 709-717.
5. Xie H, Song J, Du R, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis, 2007, 39(2): 167-172.
6. Korita PV, Wakai T, Shirai Y, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol, 2008, 39(12): 1777-1783.
7. Yang GH, Fan J, Xu Y, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist, 2008, 13(11): 1155-1165.
8. Kim JY, Bae BN, Kim KS, et al. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat, 2009, 41(1): 29-35.
9. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 2003, 98(1): 119-127.
10. Sieghart W, Wang X, Schmid K, et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol, 2011, 54(1): 89-97.
11. Tsai WC, Tsai WC, Lee HS, et al. Association between osteopontin and EGFR expression with clinicopathological parameters in hepatocellular carcinoma. Chin J Physiol, 2012, 55(6): 412-420.
12. Deng B, Zhang XF, Zhu XC, et al. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection. Oncol Rep, 2013, 30(6): 2795-2803.
13. Jin Y, Chen JN, Feng ZY, et al. OPN and αvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma. PLoS One, 2014, 9(2): e87930.
14. Ying X, Zhao Y, Wang JL, et al. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. Oncol Rep, 2014, 32(4): 1550-1556.
15. Chimparlee N, Chuaypen N, Khlaiphuengsin A, et al. Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis B-related hepatocellular carcinoma. Asian Pac J Cancer Prev, 2015, 16(16): 7211-7217.
16. 王代宏, 王偉, 王芳元. 聯合檢測 VEGF、OPN 對原發性肝癌術后復發轉移及預后的意義. 湖北科技學院學報: 醫學版, 2015, 29(4): 280-283.
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
18. Oldberg A, Franzén A, Heineg?rd D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A, 1986, 83(23): 8819-8823.
19. Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 2007, 56(6): 782-789.
20. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 2003, 9(4): 416-423.
21. 許英藝, 張雅雅, 盧偉鋒, 等. 骨橋蛋白表達與中國人肝癌及其臨床病理特征關系的 Meta 分析. 中國循證醫學雜志, 2014, 14(12): 1418-1423.
22. Zhang CH, Xu GL, Jia WD, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer, 2012, 130(11): 2685-2692.
23. Cheng J, Wang W, Sun C, et al. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol, 2014, 48(9): 806-814.
24. Caruso DJ, Carmack AJ, Lokeshwar VB, et al. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res, 2008, 14(13): 4111-4118.
25. Park MG, Oh MM, Yoon JH, et al. The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: a prospective study. Kaohsiung J Med Sci, 2012, 28(10): 526-530.
26. Briese J, Cheng S, Ezzat S, et al. Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res, 2010, 30(5): 1681-1688.
27. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004, 10(1 Pt 1): 184-190.
28. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012, 55(2): 483-490.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The prognostic value of osteopontin expression in patients with liver cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content